Skip to main navigation Skip to search Skip to main content

Pharmacokinetic interactions between buprenorphine and antiretroviral medications

  • R. Douglas Bruce
  • , Elinore McCance-Katz
  • , Evan D. Kharasch
  • , David E. Moody
  • , Gene D. Morse
  • Yale University
  • Virginia Commonwealth University
  • Washington University St. Louis
  • University of Utah

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations

Abstract

Buprenorphine is used for the treatment of opioid dependence. As the number of persons receiving buprenorphine treatment and antiretroviral therapy continues to grow, so too does the existence and clinical impact of drug interactions between buprenorphine and medications for treating human immunodeficiency virus (HIV) infection. Awareness that such interactions exist may deter some patients and physicians from initiating potentially lifesaving therapy or lead to complications among patients whose treatment is already under way. Complications include nonadherence to antiretroviral therapy and the development of viral resistance. Illicit drug use is a frequent consequence of adverse drug effects experienced by injection drug users. The occurrence of unrecognized drug interactions can lead to unsuccessful therapy for HIV infection and the treatment of substance dependence. The present review is organized to provide a working background of buprenorphine pharmacology. Review of the current state of knowledge regarding specific interactions between buprenorphine and antiretrovirals is followed by a review of the clinical applicability of these interactions.

Original languageEnglish
Pages (from-to)S216-S223
JournalClinical Infectious Diseases
Volume43
Issue numberSUPPL. 4
DOIs
StatePublished - Dec 15 2006

Fingerprint

Dive into the research topics of 'Pharmacokinetic interactions between buprenorphine and antiretroviral medications'. Together they form a unique fingerprint.

Cite this